RESEARCH TRIANGLE PARK, N.C. — Metabolon is rolling out a new product designed to help drug companies monitor the effects of drugs in clinical trials.
The mProveClinical service monitors the biochemical and physiological effects of drug candidates on samples of tissues taken from humans with the intent of helping companies make more informed decisions about drug candidates. Metabolon said.
Metabolon recently launched a drug discovery product, mSelect.
Metabolon has developed patented technology around metabolomics (an approach to identifying biomarkers) that it says will “dramatically impact drug discovery and development processes.”